Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 3OCU410Positive

AI Analysis

Summary

Ocugen announced the first patient dosed in the Phase 3 registrational trial of OCU410, its first-in-class modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The company also highlighted that OCU410 received FDA RMAT designation, supporting an accelerated development and review pathway.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in global Phase 3 registrational trial; FDA RMAT designation granted

Importance:7/10

Sentiment:

0.70

Gene therapyPhase 3FDA RMAT designationGeographic atrophyDry AMDFirst-in-classAccelerated pathway

Related Companies

$OCGN

Read the original article

Published by GlobeNewswire Clinical Studies on September 1, 2026 11:02 AM

Read Original